On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they...
"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts...
"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than...